nodes	percent_of_prediction	percent_of_DWPC	metapath
Acetazolamide—Metabolic acidosis—Teniposide—lymphatic system cancer	0.0444	0.0444	CcSEcCtD
Acetazolamide—Metabolic acidosis—Fludarabine—lymphatic system cancer	0.039	0.039	CcSEcCtD
Acetazolamide—Hepatic insufficiency—Methotrexate—lymphatic system cancer	0.0296	0.0296	CcSEcCtD
Acetazolamide—Digestion impaired—Fludarabine—lymphatic system cancer	0.0231	0.0231	CcSEcCtD
Acetazolamide—Numbness—Fludarabine—lymphatic system cancer	0.0186	0.0186	CcSEcCtD
Acetazolamide—Sensory loss—Fludarabine—lymphatic system cancer	0.0178	0.0178	CcSEcCtD
Acetazolamide—Hepatic function abnormal—Teniposide—lymphatic system cancer	0.0146	0.0146	CcSEcCtD
Acetazolamide—Reaction gastrointestinal—Methotrexate—lymphatic system cancer	0.0137	0.0137	CcSEcCtD
Acetazolamide—Hepatic failure—Fludarabine—lymphatic system cancer	0.0125	0.0125	CcSEcCtD
Acetazolamide—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.0124	0.0124	CcSEcCtD
Acetazolamide—Injection site pain—Carmustine—lymphatic system cancer	0.0121	0.0121	CcSEcCtD
Acetazolamide—Numbness—Vincristine—lymphatic system cancer	0.0114	0.0114	CcSEcCtD
Acetazolamide—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.0113	0.0113	CcSEcCtD
Acetazolamide—Tinnitus—Mechlorethamine—lymphatic system cancer	0.0112	0.0112	CcSEcCtD
Acetazolamide—Sensory loss—Vincristine—lymphatic system cancer	0.0109	0.0109	CcSEcCtD
Acetazolamide—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Acetazolamide—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00932	0.00932	CcSEcCtD
Acetazolamide—Appetite absent—Methotrexate—lymphatic system cancer	0.0092	0.0092	CcSEcCtD
Acetazolamide—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00856	0.00856	CcSEcCtD
Acetazolamide—Urine output increased—Vincristine—lymphatic system cancer	0.00853	0.00853	CcSEcCtD
Acetazolamide—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.0085	0.0085	CcSEcCtD
Acetazolamide—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00832	0.00832	CcSEcCtD
Acetazolamide—Haematuria—Fludarabine—lymphatic system cancer	0.00823	0.00823	CcSEcCtD
Acetazolamide—Flushing—Teniposide—lymphatic system cancer	0.00818	0.00818	CcSEcCtD
Acetazolamide—Polyuria—Vincristine—lymphatic system cancer	0.0078	0.0078	CcSEcCtD
Acetazolamide—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.00771	0.00771	CcSEcCtD
Acetazolamide—Hepatic failure—Vincristine—lymphatic system cancer	0.00762	0.00762	CcSEcCtD
Acetazolamide—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00739	0.00739	CcSEcCtD
Acetazolamide—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00733	0.00733	CcSEcCtD
Acetazolamide—Hyponatraemia—Carmustine—lymphatic system cancer	0.0072	0.0072	CcSEcCtD
Acetazolamide—Agitation—Teniposide—lymphatic system cancer	0.00705	0.00705	CcSEcCtD
Acetazolamide—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.00689	0.00689	CcSEcCtD
Acetazolamide—Hyponatraemia—Vincristine—lymphatic system cancer	0.00687	0.00687	CcSEcCtD
Acetazolamide—Leukopenia—Teniposide—lymphatic system cancer	0.00687	0.00687	CcSEcCtD
Acetazolamide—Ataxia—Carmustine—lymphatic system cancer	0.00674	0.00674	CcSEcCtD
Acetazolamide—Hyponatraemia—Mitoxantrone—lymphatic system cancer	0.00669	0.00669	CcSEcCtD
Acetazolamide—Hypokalaemia—Carmustine—lymphatic system cancer	0.00653	0.00653	CcSEcCtD
Acetazolamide—Ataxia—Vincristine—lymphatic system cancer	0.00644	0.00644	CcSEcCtD
Acetazolamide—Confusional state—Teniposide—lymphatic system cancer	0.00632	0.00632	CcSEcCtD
Acetazolamide—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00626	0.00626	CcSEcCtD
Acetazolamide—Agitation—Fludarabine—lymphatic system cancer	0.0062	0.0062	CcSEcCtD
Acetazolamide—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00613	0.00613	CcSEcCtD
Acetazolamide—Malaise—Fludarabine—lymphatic system cancer	0.00608	0.00608	CcSEcCtD
Acetazolamide—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.00607	0.00607	CcSEcCtD
Acetazolamide—Leukopenia—Fludarabine—lymphatic system cancer	0.00604	0.00604	CcSEcCtD
Acetazolamide—Haematuria—Bleomycin—lymphatic system cancer	0.00604	0.00604	CcSEcCtD
Acetazolamide—Convulsion—Fludarabine—lymphatic system cancer	0.00585	0.00585	CcSEcCtD
Acetazolamide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00581	0.00581	CcSEcCtD
Acetazolamide—Discomfort—Fludarabine—lymphatic system cancer	0.00568	0.00568	CcSEcCtD
Acetazolamide—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00565	0.00565	CcSEcCtD
Acetazolamide—Confusional state—Fludarabine—lymphatic system cancer	0.00555	0.00555	CcSEcCtD
Acetazolamide—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00551	0.00551	CcSEcCtD
Acetazolamide—Decreased appetite—Teniposide—lymphatic system cancer	0.00545	0.00545	CcSEcCtD
Acetazolamide—Vomiting—Mechlorethamine—lymphatic system cancer	0.0054	0.0054	CcSEcCtD
Acetazolamide—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.0054	0.0054	CcSEcCtD
Acetazolamide—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00539	0.00539	CcSEcCtD
Acetazolamide—Flushing—Bleomycin—lymphatic system cancer	0.00527	0.00527	CcSEcCtD
Acetazolamide—Feeling abnormal—Teniposide—lymphatic system cancer	0.00516	0.00516	CcSEcCtD
Acetazolamide—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00514	0.00514	CcSEcCtD
Acetazolamide—Nausea—Mechlorethamine—lymphatic system cancer	0.00505	0.00505	CcSEcCtD
Acetazolamide—Urticaria—Teniposide—lymphatic system cancer	0.00498	0.00498	CcSEcCtD
Acetazolamide—Body temperature increased—Teniposide—lymphatic system cancer	0.00495	0.00495	CcSEcCtD
Acetazolamide—Paraesthesia—Fludarabine—lymphatic system cancer	0.00494	0.00494	CcSEcCtD
Acetazolamide—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00494	0.00494	CcSEcCtD
Acetazolamide—Haematuria—Mitoxantrone—lymphatic system cancer	0.0049	0.0049	CcSEcCtD
Acetazolamide—Dyspepsia—Fludarabine—lymphatic system cancer	0.00485	0.00485	CcSEcCtD
Acetazolamide—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00479	0.00479	CcSEcCtD
Acetazolamide—Decreased appetite—Fludarabine—lymphatic system cancer	0.00479	0.00479	CcSEcCtD
Acetazolamide—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00475	0.00475	CcSEcCtD
Acetazolamide—Fatigue—Fludarabine—lymphatic system cancer	0.00475	0.00475	CcSEcCtD
Acetazolamide—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00471	0.00471	CcSEcCtD
Acetazolamide—Flushing—Carmustine—lymphatic system cancer	0.0046	0.0046	CcSEcCtD
Acetazolamide—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00459	0.00459	CcSEcCtD
Acetazolamide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00454	0.00454	CcSEcCtD
Acetazolamide—Asthenia—Teniposide—lymphatic system cancer	0.0045	0.0045	CcSEcCtD
Acetazolamide—Melaena—Methotrexate—lymphatic system cancer	0.00447	0.00447	CcSEcCtD
Acetazolamide—Malaise—Bleomycin—lymphatic system cancer	0.00446	0.00446	CcSEcCtD
Acetazolamide—Leukopenia—Bleomycin—lymphatic system cancer	0.00443	0.00443	CcSEcCtD
Acetazolamide—Body temperature increased—Fludarabine—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Acetazolamide—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.0043	0.0043	CcSEcCtD
Acetazolamide—Diarrhoea—Teniposide—lymphatic system cancer	0.00429	0.00429	CcSEcCtD
Acetazolamide—Discomfort—Bleomycin—lymphatic system cancer	0.00416	0.00416	CcSEcCtD
Acetazolamide—Urine output increased—Methotrexate—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Acetazolamide—Confusional state—Bleomycin—lymphatic system cancer	0.00407	0.00407	CcSEcCtD
Acetazolamide—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00404	0.00404	CcSEcCtD
Acetazolamide—Vomiting—Teniposide—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Acetazolamide—Agitation—Carmustine—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Acetazolamide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Acetazolamide—Asthenia—Fludarabine—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Acetazolamide—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Acetazolamide—Headache—Teniposide—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Acetazolamide—Leukopenia—Carmustine—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Acetazolamide—Agitation—Vincristine—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Acetazolamide—Photosensitivity—Methotrexate—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Acetazolamide—Polyuria—Methotrexate—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Acetazolamide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Acetazolamide—Convulsion—Carmustine—lymphatic system cancer	0.00374	0.00374	CcSEcCtD
Acetazolamide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Acetazolamide—Nausea—Teniposide—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Acetazolamide—Hepatic failure—Methotrexate—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Acetazolamide—Leukopenia—Vincristine—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Acetazolamide—Paraesthesia—Bleomycin—lymphatic system cancer	0.00363	0.00363	CcSEcCtD
Acetazolamide—Malaise—Mitoxantrone—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Acetazolamide—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Acetazolamide—Convulsion—Vincristine—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Acetazolamide—Confusional state—Carmustine—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Acetazolamide—Decreased appetite—Bleomycin—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Acetazolamide—Vomiting—Fludarabine—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Acetazolamide—Convulsion—Mitoxantrone—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Acetazolamide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Acetazolamide—Headache—Fludarabine—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Acetazolamide—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Acetazolamide—Discomfort—Mitoxantrone—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Acetazolamide—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Acetazolamide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Acetazolamide—Confusional state—Mitoxantrone—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Acetazolamide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Acetazolamide—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Acetazolamide—Nausea—Fludarabine—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Acetazolamide—Shock—Mitoxantrone—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Acetazolamide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Acetazolamide—Urticaria—Bleomycin—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Acetazolamide—Body temperature increased—Bleomycin—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Acetazolamide—Irritability—Methotrexate—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Acetazolamide—Paraesthesia—Carmustine—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Acetazolamide—Somnolence—Carmustine—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Acetazolamide—Ataxia—Methotrexate—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Acetazolamide—Decreased appetite—Carmustine—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Acetazolamide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Acetazolamide—Paraesthesia—Vincristine—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Acetazolamide—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Acetazolamide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00294	0.00294	CcSEcCtD
Acetazolamide—Decreased appetite—Vincristine—lymphatic system cancer	0.00292	0.00292	CcSEcCtD
Acetazolamide—Somnolence—Mitoxantrone—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Acetazolamide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Acetazolamide—Feeling abnormal—Carmustine—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Acetazolamide—Fatigue—Vincristine—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Acetazolamide—Asthenia—Bleomycin—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Acetazolamide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Acetazolamide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Acetazolamide—Fatigue—Mitoxantrone—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Acetazolamide—Body temperature increased—Carmustine—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Acetazolamide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Acetazolamide—Body temperature increased—Vincristine—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Acetazolamide—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Acetazolamide—Urticaria—Mitoxantrone—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Acetazolamide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Acetazolamide—Vomiting—Bleomycin—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Acetazolamide—Drowsiness—Methotrexate—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Acetazolamide—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Acetazolamide—Asthenia—Carmustine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Acetazolamide—Haematuria—Methotrexate—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Acetazolamide—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Acetazolamide—Asthenia—Vincristine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Acetazolamide—Diarrhoea—Carmustine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Acetazolamide—Nausea—Bleomycin—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Acetazolamide—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Acetazolamide—Asthenia—Mitoxantrone—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Acetazolamide—Dizziness—Carmustine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Acetazolamide—Diarrhoea—Vincristine—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Acetazolamide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Acetazolamide—Vomiting—Carmustine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Acetazolamide—Dizziness—Vincristine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Acetazolamide—Headache—Carmustine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Acetazolamide—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Acetazolamide—Tinnitus—Methotrexate—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Acetazolamide—Vomiting—Vincristine—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Acetazolamide—Headache—Vincristine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Acetazolamide—Nausea—Carmustine—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Acetazolamide—Vomiting—Mitoxantrone—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Acetazolamide—Headache—Mitoxantrone—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Acetazolamide—Nausea—Vincristine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Acetazolamide—Dysgeusia—Methotrexate—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Acetazolamide—Nausea—Mitoxantrone—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Acetazolamide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Acetazolamide—Malaise—Methotrexate—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Acetazolamide—Leukopenia—Methotrexate—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Acetazolamide—Convulsion—Methotrexate—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Acetazolamide—Discomfort—Methotrexate—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Acetazolamide—Confusional state—Methotrexate—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Acetazolamide—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Acetazolamide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Acetazolamide—Paraesthesia—Methotrexate—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Acetazolamide—Somnolence—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Acetazolamide—Dyspepsia—Methotrexate—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Acetazolamide—Decreased appetite—Methotrexate—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Acetazolamide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Acetazolamide—Fatigue—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Acetazolamide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Acetazolamide—Urticaria—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Acetazolamide—Body temperature increased—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Acetazolamide—Asthenia—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Acetazolamide—Diarrhoea—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Acetazolamide—Dizziness—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Acetazolamide—Vomiting—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Acetazolamide—Headache—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Acetazolamide—Nausea—Methotrexate—lymphatic system cancer	0.00097	0.00097	CcSEcCtD
